Syndesome therapeutics for enhancing diabetic wound healing

Subhamoy Das, Gunjan Singh, Marjan Majid, Michael Sherman, Somshuvra Mukhopadhyay, Catherine S. Wright, Patricia E. Martin, Andrew K. Dunn, Aaron B. Baker

Research output: Contribution to journalArticle

31 Downloads (Pure)

Abstract

Chronic wounds represent a major healthcare and economic problem worldwide. Advanced wound dressings that incorporate bioactive compounds have great potential for improving outcomes in patients with chronic wounds but significant challenges in designing treatments that are effective in long-standing, nonhealing wounds. Here, an optimized wound healing gel was developed that delivers syndecan-4 proteoliposomes (“syndesomes”) with fibroblast growth factor-2 (FGF-2) to enhance diabetic wound healing. In vitro studies demonstrate that syndesomes markedly increase migration of keratinocytes and fibroblasts isolated from both nondiabetic and diabetic donors. In addition, syndesome treatment leads to increased endocytic processing of FGF-2 that includes enhanced recycling of FGF-2 to the cell surface after uptake. The optimized syndesome formulation was incorporated into an alginate wound dressing and tested in a splinted wound model in diabetic, ob/ob mice. It was found that wounds treated with syndesomes and FGF-2 have markedly enhanced wound closure in comparison to wounds treated with only FGF-2. Moreover, syndesomes have an immunomodulatory effect on wound macrophages, leading to a shift toward the M2 macrophage phenotype and alterations in the wound cytokine profile. Together, these studies show that delivery of exogenous syndecan-4 is an effective method for enhancing wound healing in the long-term diabetic diseased state.
Original languageEnglish
Pages (from-to)2248-2260
Number of pages13
JournalAdvanced Healthcare Materials
Volume5
Issue number17
Early online date6 Jul 2016
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Syndecan-4
Fibroblasts
Wound Healing
Fibroblast Growth Factor 2
Wounds and Injuries
Macrophages
Therapeutics
Bandages
Alginate
Recycling
Gels
proteoliposomes
Intercellular Signaling Peptides and Proteins
Economics
Cytokines
Keratinocytes
Processing

Keywords

  • diabetes
  • wound healing
  • bioactive compounds

Cite this

Das, S., Singh, G., Majid, M., Sherman, M., Mukhopadhyay, S., Wright, C. S., ... Baker, A. B. (2016). Syndesome therapeutics for enhancing diabetic wound healing. Advanced Healthcare Materials, 5(17), 2248-2260. https://doi.org/10.1002/adhm.201600285
Das, Subhamoy ; Singh, Gunjan ; Majid, Marjan ; Sherman, Michael ; Mukhopadhyay, Somshuvra ; Wright, Catherine S. ; Martin, Patricia E. ; Dunn, Andrew K. ; Baker, Aaron B. / Syndesome therapeutics for enhancing diabetic wound healing. In: Advanced Healthcare Materials. 2016 ; Vol. 5, No. 17. pp. 2248-2260.
@article{c95004b9b9484d4ea7606f003884a1ed,
title = "Syndesome therapeutics for enhancing diabetic wound healing",
abstract = "Chronic wounds represent a major healthcare and economic problem worldwide. Advanced wound dressings that incorporate bioactive compounds have great potential for improving outcomes in patients with chronic wounds but significant challenges in designing treatments that are effective in long-standing, nonhealing wounds. Here, an optimized wound healing gel was developed that delivers syndecan-4 proteoliposomes (“syndesomes”) with fibroblast growth factor-2 (FGF-2) to enhance diabetic wound healing. In vitro studies demonstrate that syndesomes markedly increase migration of keratinocytes and fibroblasts isolated from both nondiabetic and diabetic donors. In addition, syndesome treatment leads to increased endocytic processing of FGF-2 that includes enhanced recycling of FGF-2 to the cell surface after uptake. The optimized syndesome formulation was incorporated into an alginate wound dressing and tested in a splinted wound model in diabetic, ob/ob mice. It was found that wounds treated with syndesomes and FGF-2 have markedly enhanced wound closure in comparison to wounds treated with only FGF-2. Moreover, syndesomes have an immunomodulatory effect on wound macrophages, leading to a shift toward the M2 macrophage phenotype and alterations in the wound cytokine profile. Together, these studies show that delivery of exogenous syndecan-4 is an effective method for enhancing wound healing in the long-term diabetic diseased state.",
keywords = "diabetes, wound healing, bioactive compounds",
author = "Subhamoy Das and Gunjan Singh and Marjan Majid and Michael Sherman and Somshuvra Mukhopadhyay and Wright, {Catherine S.} and Martin, {Patricia E.} and Dunn, {Andrew K.} and Baker, {Aaron B.}",
note = "Acceptance email and AAM requested Acceptance email in SAN AAM: provided 25-4-17; 12m embargo Exception email in SAN ^Exception status: author email in SAN; agreed no exception can be applied (library exception review, October 2018)",
year = "2016",
month = "9",
doi = "10.1002/adhm.201600285",
language = "English",
volume = "5",
pages = "2248--2260",
journal = "Advanced Healthcare Materials",
issn = "2192-2640",
publisher = "John Wiley & Sons",
number = "17",

}

Das, S, Singh, G, Majid, M, Sherman, M, Mukhopadhyay, S, Wright, CS, Martin, PE, Dunn, AK & Baker, AB 2016, 'Syndesome therapeutics for enhancing diabetic wound healing', Advanced Healthcare Materials, vol. 5, no. 17, pp. 2248-2260. https://doi.org/10.1002/adhm.201600285

Syndesome therapeutics for enhancing diabetic wound healing. / Das, Subhamoy; Singh, Gunjan; Majid, Marjan; Sherman, Michael; Mukhopadhyay, Somshuvra; Wright, Catherine S.; Martin, Patricia E.; Dunn, Andrew K.; Baker, Aaron B.

In: Advanced Healthcare Materials, Vol. 5, No. 17, 09.2016, p. 2248-2260.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Syndesome therapeutics for enhancing diabetic wound healing

AU - Das, Subhamoy

AU - Singh, Gunjan

AU - Majid, Marjan

AU - Sherman, Michael

AU - Mukhopadhyay, Somshuvra

AU - Wright, Catherine S.

AU - Martin, Patricia E.

AU - Dunn, Andrew K.

AU - Baker, Aaron B.

N1 - Acceptance email and AAM requested Acceptance email in SAN AAM: provided 25-4-17; 12m embargo Exception email in SAN ^Exception status: author email in SAN; agreed no exception can be applied (library exception review, October 2018)

PY - 2016/9

Y1 - 2016/9

N2 - Chronic wounds represent a major healthcare and economic problem worldwide. Advanced wound dressings that incorporate bioactive compounds have great potential for improving outcomes in patients with chronic wounds but significant challenges in designing treatments that are effective in long-standing, nonhealing wounds. Here, an optimized wound healing gel was developed that delivers syndecan-4 proteoliposomes (“syndesomes”) with fibroblast growth factor-2 (FGF-2) to enhance diabetic wound healing. In vitro studies demonstrate that syndesomes markedly increase migration of keratinocytes and fibroblasts isolated from both nondiabetic and diabetic donors. In addition, syndesome treatment leads to increased endocytic processing of FGF-2 that includes enhanced recycling of FGF-2 to the cell surface after uptake. The optimized syndesome formulation was incorporated into an alginate wound dressing and tested in a splinted wound model in diabetic, ob/ob mice. It was found that wounds treated with syndesomes and FGF-2 have markedly enhanced wound closure in comparison to wounds treated with only FGF-2. Moreover, syndesomes have an immunomodulatory effect on wound macrophages, leading to a shift toward the M2 macrophage phenotype and alterations in the wound cytokine profile. Together, these studies show that delivery of exogenous syndecan-4 is an effective method for enhancing wound healing in the long-term diabetic diseased state.

AB - Chronic wounds represent a major healthcare and economic problem worldwide. Advanced wound dressings that incorporate bioactive compounds have great potential for improving outcomes in patients with chronic wounds but significant challenges in designing treatments that are effective in long-standing, nonhealing wounds. Here, an optimized wound healing gel was developed that delivers syndecan-4 proteoliposomes (“syndesomes”) with fibroblast growth factor-2 (FGF-2) to enhance diabetic wound healing. In vitro studies demonstrate that syndesomes markedly increase migration of keratinocytes and fibroblasts isolated from both nondiabetic and diabetic donors. In addition, syndesome treatment leads to increased endocytic processing of FGF-2 that includes enhanced recycling of FGF-2 to the cell surface after uptake. The optimized syndesome formulation was incorporated into an alginate wound dressing and tested in a splinted wound model in diabetic, ob/ob mice. It was found that wounds treated with syndesomes and FGF-2 have markedly enhanced wound closure in comparison to wounds treated with only FGF-2. Moreover, syndesomes have an immunomodulatory effect on wound macrophages, leading to a shift toward the M2 macrophage phenotype and alterations in the wound cytokine profile. Together, these studies show that delivery of exogenous syndecan-4 is an effective method for enhancing wound healing in the long-term diabetic diseased state.

KW - diabetes

KW - wound healing

KW - bioactive compounds

U2 - 10.1002/adhm.201600285

DO - 10.1002/adhm.201600285

M3 - Article

VL - 5

SP - 2248

EP - 2260

JO - Advanced Healthcare Materials

JF - Advanced Healthcare Materials

SN - 2192-2640

IS - 17

ER -